Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 10/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625274 | 1.00 | ATR (0.44) | ATRLMNAPDGFRBFGFR1KDR | |
| SCHEMBL1283946 | 0.96 | ATR (0.46) | ATRLMNAPDGFRBFGFR1KDR | |
| SCHEMBL1283949 | 0.96 | ATR (0.46) | ATRLMNAPDGFRBFGFR1KDR | |
| SCHEMBL1284155 | 0.96 | ATR (0.46) | ATRLMNAPDGFRBFGFR1KDR | |
| SCHEMBL1284808 | 0.91 | PDGFRB (0.47) | ATRLMNAPDGFRBFGFR1KDR | |
| SCHEMBL1624583 | 0.91 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL1284559 | 0.91 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL1284557 | 0.91 | DGAT2 (0.51) | LMNADGAT2NOTUM | |
| SCHEMBL1625258 | 0.91 | DGAT2 (0.45) | ATRDGAT2NOTUM | |
| SCHEMBL1624030 | 0.91 | DGAT2 (0.45) | ATRDGAT2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | ATR 3196/4885LMNA 4481/4885PDGFRB 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.